YMAB vs. HRTX, AMRN, AUPH, MRSN, GBIO, AMPH, AMRX, RCKT, ARVN, and ZLAB
Should you be buying Y-mAbs Therapeutics stock or one of its competitors? The main competitors of Y-mAbs Therapeutics include Heron Therapeutics (HRTX), Amarin (AMRN), Aurinia Pharmaceuticals (AUPH), Mersana Therapeutics (MRSN), Generation Bio (GBIO), Amphastar Pharmaceuticals (AMPH), Amneal Pharmaceuticals (AMRX), Rocket Pharmaceuticals (RCKT), Arvinas (ARVN), and Zai Lab (ZLAB). These companies are all part of the "pharmaceutical preparations" industry.
Y-mAbs Therapeutics (NASDAQ:YMAB) and Heron Therapeutics (NASDAQ:HRTX) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, institutional ownership, community ranking, dividends, risk, profitability, analyst recommendations, valuation and media sentiment.
70.9% of Y-mAbs Therapeutics shares are owned by institutional investors. Comparatively, 80.0% of Heron Therapeutics shares are owned by institutional investors. 21.5% of Y-mAbs Therapeutics shares are owned by company insiders. Comparatively, 6.4% of Heron Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Heron Therapeutics received 538 more outperform votes than Y-mAbs Therapeutics when rated by MarketBeat users. Likewise, 69.01% of users gave Heron Therapeutics an outperform vote while only 60.71% of users gave Y-mAbs Therapeutics an outperform vote.
Y-mAbs Therapeutics has higher earnings, but lower revenue than Heron Therapeutics. Y-mAbs Therapeutics is trading at a lower price-to-earnings ratio than Heron Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, Y-mAbs Therapeutics had 1 more articles in the media than Heron Therapeutics. MarketBeat recorded 3 mentions for Y-mAbs Therapeutics and 2 mentions for Heron Therapeutics. Heron Therapeutics' average media sentiment score of 0.99 beat Y-mAbs Therapeutics' score of 0.90 indicating that Heron Therapeutics is being referred to more favorably in the news media.
Y-mAbs Therapeutics has a beta of 0.69, suggesting that its share price is 31% less volatile than the S&P 500. Comparatively, Heron Therapeutics has a beta of 1.81, suggesting that its share price is 81% more volatile than the S&P 500.
Y-mAbs Therapeutics has a net margin of -25.64% compared to Heron Therapeutics' net margin of -61.28%. Heron Therapeutics' return on equity of 0.00% beat Y-mAbs Therapeutics' return on equity.
Y-mAbs Therapeutics currently has a consensus price target of $17.33, indicating a potential upside of 44.32%. Heron Therapeutics has a consensus price target of $5.50, indicating a potential upside of 49.05%. Given Heron Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Heron Therapeutics is more favorable than Y-mAbs Therapeutics.
Summary
Heron Therapeutics beats Y-mAbs Therapeutics on 10 of the 18 factors compared between the two stocks.
Get Y-mAbs Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for YMAB and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding YMAB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Y-mAbs Therapeutics Competitors List
Related Companies and Tools
